•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Fosamax
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Were you diagnosed with Osteonecrosis of the Jawbone (ONJ)?


Please describe ONJ symptoms and treatment:

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Merck's Fosamax next legal battleground?

Apr 12, 2006 | UPI In the wake of the recent $15 million Vioxx verdict, plaintiffs' attorneys are already setting their sights on Merck's Fosamax.

That according to a Wall Street Journal report Wednesday, which said that Merck's top-selling osteoporosis drug Fosamax is the second drug made by the embattled company to come into the crosshairs of the medical tort bar. A lawsuit was filed this week in Fort Myers, Fla., the report said, with the plaintiffs seeking class-action status.

According to the WSJ, the suit alleges Fosamax caused a rare disorder called osteonecrosis, in which the patient's jawbone "rots and dies." A similar suit was filed in Tennessee last fall, the report said.

Following the legal strategy used in the widely publicized Vioxx-related cases brought against Merck, the Florida-based Fosamax suit alleges that Merck "heavily marketed" Fosamax as safe despite the risk of the rare side effect.